This document is an excerpt from the EUR-Lex website
Document 62021CA0702
Case C-702/21 P: Judgment of the Court (Eighth Chamber) of 10 November 2022 — Laboratoire Pareva v Biotech3D Ltd & Co. KG, European Commission, French Republic, European Chemicals Agency (Appeal — Biocidal products — Regulation (EU) No 528/2012 — Delegated Regulation (EU) No 1062/2014 — Active substance PHMB (1415; 4.7) — Refusal of approval as an existing active substance for use in biocidal products of product-types 1, 5 and 6 — Approval as an existing active substance for use in biocidal products of product-types 2 and 4 — Teratogenic effect — Human health risk assessment)
Case C-702/21 P: Judgment of the Court (Eighth Chamber) of 10 November 2022 — Laboratoire Pareva v Biotech3D Ltd & Co. KG, European Commission, French Republic, European Chemicals Agency (Appeal — Biocidal products — Regulation (EU) No 528/2012 — Delegated Regulation (EU) No 1062/2014 — Active substance PHMB (1415; 4.7) — Refusal of approval as an existing active substance for use in biocidal products of product-types 1, 5 and 6 — Approval as an existing active substance for use in biocidal products of product-types 2 and 4 — Teratogenic effect — Human health risk assessment)
Case C-702/21 P: Judgment of the Court (Eighth Chamber) of 10 November 2022 — Laboratoire Pareva v Biotech3D Ltd & Co. KG, European Commission, French Republic, European Chemicals Agency (Appeal — Biocidal products — Regulation (EU) No 528/2012 — Delegated Regulation (EU) No 1062/2014 — Active substance PHMB (1415; 4.7) — Refusal of approval as an existing active substance for use in biocidal products of product-types 1, 5 and 6 — Approval as an existing active substance for use in biocidal products of product-types 2 and 4 — Teratogenic effect — Human health risk assessment)
OJ C 7, 9.1.2023, p. 13–13
(BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
- Date of document:
- 10/11/2022
- Date lodged:
- 19/11/2021
- Author:
- Court of Justice
- Form:
- Judicial information
- Authentic language:
- English
- Type of procedure:
- Appeal - unfounded, Action for annulment
- Link
- Select all documents mentioning this document
- Case affecting:
-
- Related EU case-law document 62021CJ0702
- Instruments cited in case law:
- Link
|
9.1.2023 |
EN |
Official Journal of the European Union |
C 7/13 |
Judgment of the Court (Eighth Chamber) of 10 November 2022 — Laboratoire Pareva v Biotech3D Ltd & Co. KG, European Commission, French Republic, European Chemicals Agency
(Case C-702/21 P) (1)
(Appeal - Biocidal products - Regulation (EU) No 528/2012 - Delegated Regulation (EU) No 1062/2014 - Active substance PHMB (1415; 4.7) - Refusal of approval as an existing active substance for use in biocidal products of product-types 1, 5 and 6 - Approval as an existing active substance for use in biocidal products of product-types 2 and 4 - Teratogenic effect - Human health risk assessment)
(2023/C 7/15)
Language of the case: English
Parties
Appellant: Laboratoire Pareva (represented by S. Englebert, M. Grunchard and M. Ombredane, avocats, P. Sellar, advocaat, and by K. Van Maldegem, avocat)
Other parties to the proceedings: Biotech3D Ltd & Co. KG, European Commission (represented by R. Lindenthal and K. Mifsud-Bonnici, acting as Agents), French Republic (represented by G. Bain and J.-L. Carré, acting as Agents), European Chemicals Agency (ECHA) (represented by C. Buchanan, M. Heikkilä and T. Zbihlej, acting as Agents)
Operative part of the judgment
The Court:
|
1. |
Dismisses the appeal; |
|
2. |
Orders Laboratoire Pareva to pay the costs; |
|
3. |
Orders the French Republic to bear its own costs. |
